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Genomic alterations accompanying tumour
evolution in colorectal cancer: tracking the
differences between primary tumours and
synchronous liver metastases by whole-
exome sequencing
M. B. Mogensen1*, M. Rossing2, O. Østrup2, P. N. Larsen3, P. J. Heiberg Engel4, L. N. Jørgensen5, E. V. Hogdall6,
J. Eriksen7, P. Ibsen8, P. Jess9, M. Grauslund11, H. J. Nielsen10, F. C. Nielsen2, B. Vainer11 and K. Osterlind1
Abstract
Background: Colorectal cancer (CRC) patients with metastatic disease can become cured if neoadjuvant treatment
can enable a resection. The search for predictive biomarkers is often performed on primary tumours tissue. In order
to assess the effectiveness of tailored treatment in regard to the primary tumour the differences in the genomic
profile needs to be clarified.
Methods: Fresh-frozen tissue from primary tumours, synchronous liver metastases and adjacent normal liver was
collected from 21 patients and analysed by whole-exome sequencing on the Illumina HiSeq 2500 platform. Gene
variants designated as ‘damaging’ or ‘potentially damaging’ by Ingenuity software were used for the subsequent
comparative analysis. BAM files were used as the input for the analysis of CNAs using NEXUS software.
Results: Shared mutations between the primary tumours and the synchronous liver metastases varied from 50 to 96%.
Mutations in APC, KRAS, NRAS, TP53 or BRAF were concordant between the primary tumours and the metastases. Among
the private mutations were well-known driver genes such as PIK3CA and SMAD4. The number of mutations was
significantly higher in patients with right- compared to left-sided tumours (102 vs. 66, p = 0.004). Furthermore,
right- compared to left-sided tumours had a significantly higher frequency of private mutations (p = 0.023). Similarly,
CNAs differed between the primary tumours and the metastases. The difference was mostly comprised of numerical
and segmental aberrations. However, novel CNAs were rarely observed in specific CRC-relevant genes.
Conclusion: The examined primary colorectal tumours and synchronous liver metastases had multiple private mutations,
indicating a high degree of inter-tumour heterogeneity in the individual patient. Moreover, the acquirement of novel
CNAs from primary tumours to metastases substantiates the need for genomic profiling of metastases in order to tailor
metastatic CRC therapies. As for the mutational status of the KRAS, NRAS and BRAF genes, no discordance was observed
between the primary tumours and the metastases.
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Background
Colorectal cancer (CRC) is the third most common type
of malignancy, accounting for 693,900 cancer-related
deaths worldwide in 2012 [1]. Approximately 20% of
patients with CRC present distant metastases at the
time of diagnosis, most often located in the liver. The
treatment of disseminated CRC has improved significantly
during the last decade, including systemic as well as surgical
treatment. This progress has enabled the cure of metastatic
disease in cases where the metastases are resectable at diag-
nosis or after neoadjuvant chemotherapy [2]. Therefore, it
is very important to select the best chemotherapy combin-
ation for neoadjuvant treatment of the individual patient. A
resected primary tumour offers an accessible archetypal
cancer tissue for the formulation of a genomic-guided treat-
ment composition. The success of such a policy depends
on whether the metastases display major differences in their
genomic and thus proteomic profiles compared to those of
the primary tumours [3, 4].
A diagnosis of CRC is in general based on biopsies
from the primary tumour followed by resection; biopsies
from metastases are rarely performed [5, 6]. Previous
studies of CRC comparing mutations in the primary
tumour and metastases from the same patient have
focused on selected mutations in a few or a restricted
panel of genes, i.e. mostly known cancer drivers such as
KRAS, BRAF and APC. Mutations in the APC and KRAS
genes appear early in tumour development and concordance
between the primary tumour and metastases is seen in 88–
100% of patients for KRAS mutations [7–11]. Due to gen-
omic instability, it is reasonable to speculate that for many
genes other than KRAS the genomic profile of metastases
may show a greater deviation from the profile of the primary
tumour. Therefore, to clarify how well the primary tumour
reflects the metastases in CRC, in the present study we
undertook whole exome sequencing for genomic profiling
of fresh tissue from synchronous primary tumours and liver
metastases.
Methods
Patients
Patients with colorectal liver metastases referred to
Rigshospitalet (RH), Copenhagen University Hospital,
during the period March 2012 to January 2014 were
eligible for the study. To be eligible, the patient’s liver
metastases had to be determined resectable at a multi-
disciplinary team conference and the patient’s primary
tumour had to still be in situ or fresh-frozen tissue from a
previously resected primary tumour, archived at the
Danish CancerBiobank, had to be available [12]. Informed,
written consent was obtained from all patients before
inclusion in the study [12]. The inclusion criteria were a
histologically confirmed adenocarcinoma, one or more
synchronous, resectable liver metastases and an in situ
primary tumour or tissue samples in the biobank. Patients
who had received neoadjuvant chemotherapy could be
included, but neoadjuvant radiotherapy was not allowed.
The study protocol was approved by The Ethics Committee
of the Capital Region of Denmark (H3–2011-150). The
study was conducted in accordance with the Helsinki
Declaration [13].
Sampling and DNA extraction
Specimens were promptly collected at surgery, put on
ice and transferred to the Pathology Department where
sampling was performed immediately after arrival according
to guidelines [12]. To allow sampling for the study, the
tumour had to be large enough to ensure sufficient material
for the standard diagnostic and staging pathologic examina-
tions. Samples from the primary tumours were frozen to −
80 °C to ensure the DNA quality and a minor tumour
fragment was formalin-fixed and paraffin embedded for
microscopy by a pathologist. Only specimens with a
tumour content of more than 70% were included in further
analyses. The sampling and preparation of tissue from the
liver resections were conducted in a similar manner. In
addition to metastasis specimens, a piece of normal
liver tissue was taken, plus a formalin-fixed specimen
for microscopy. DNA was extracted from the fresh-frozen
tissue using the NucleoSpin Tissue Kit (Macherey-Nagel
GmbH & Co. KG, Germany) according to the manufac-
turer’s instructions, with the added application of a tissue
lyzer in the lysis step. DNA quantity was assessed by
Agilent’s Bioanalyzer (USA).
Whole-exome sequencing and data processing
Enrichment of the exome was performed using Nimblegen
Exomes (Nimblegen SeqCap EZ Human Exome Library
v3.0) based on 64 Mb capture of coding region without 5′
and 3’ UTR (Nimblegen, USA). Sequencing was performed
on the Illumina HiSeq 2500 platform. In brief, 1 μg of gen-
omic DNA was fractionated on a Covaris S2 to an average
size of 200 bp. Trimming, 3′ adenylation and ligation
of Illumina TruSeq DNA adaptors were performed on
an SPRI-TE Nucleic Acid Extractor using SPRIworks
Fragment Library Cartridges I (Beckman Coulter, USA)
with a size selection of 200–400 bp. Following sequen-
cing, paired FASTQ files were generated using Illumina
CASAVA-1.8.2 software and imported into CLC Genomics
Workbench (Qiagen, Germany) for further processing.
The reads were aligned to the reference haploid human
genome sequence (Genome Reference Consortium human
genome build 37, human genome 19 (hg19)). A further
local realignment was performed to improve the alignment
of individual reads in the presence of insertions and dele-
tions relative to the reference.
From each patient three samples were sequenced and
filtered: primary tumour, liver metastasis and normal
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liver tissue. Single nucleotide variants (SNV) from normal
liver tissue were extracted from the gene variants called
from the primary tumour and liver metastases to exclude
germline variants. By the use of CLC Genomic Workbench
SNV were then filtered according to a minimum count
(> 5), a maximum count in control (< 10), coverage (> 9)
and mutation allele frequencies along with a forward-back-
ward reading demand (> 0.2). After filtering, variants were
exported as VCF files to enable Ingenuity Variant Analysis
(Qiagen, Germany) for further filtering based on predicting
of the damaging effect of variants. Classification of Ingenu-
ity is supported by data from other in silico prediction al-
gorithms such as SIFT, PolyPhen and COSMIC [14–16].
Only variants described with lower than 1% frequency in
the 1000 Genomes Project or National Heart, Lung and
Blood Institute Exome Sequencing Project were included,
because variant genes present in more than 1% of the
population are thought to be common gene variants and
not associated with a disease. In addition, the Ingenuity
Variant Analysis was performed to keep only variants
being associated with a loss of function, frameshift,
in-frame, stop codon or missense and in addition being
attributed: ‘pathogenic’ or ‘likely pathogenic’. CLC Gen-
omics Workbench was subsequently used for manual
visual control and exclusion of false positive variants.
By visual control of called variants, the same positions
were identified in the primary tumour, metastases and
normal liver tissue, ensuring that variants called private
were not caused by the filtering procedure when the fre-
quency was low and thus falsely attributed as ‘private’.
The visual control also ensured that variants called ‘pri-
vate’ were not classified as ‘private’ because the other site
was not uncovered. Variants called ‘shared’ meant not only
a mutation in the same gene but the exact same mutation
in both the primary tumour and the metastasis. The
gene variants were classified according to the SIFT sys-
tem [16] which sorts intolerant from tolerant substitu-
tions based on a prediction of potential substitution
effects on the resulting protein function, being divided
into ‘tolerated’, ‘damaging’ or ‘activating’. The SIFTclassi-
fication was called by the Ingenuity software. Driver genes,
based on a prior study reporting a list of high confidence
driver genes (291 driver genes) were identified among our
variants, but not used as a filter [17]. To estimate the
amount of mutations that was only subclonal in the primary
tumour but had a high frequency in the metastases, an in-
crease in allel frequency of > 30 from the primary tumour to
the metastases was selected (Δ30%).
Genes identified as private to the metastases were in-
cluded in a network analysis using the Ingenuity Pathway
Analysis (IPA) programme [18]. The IPA determination of
whether pathways are significantly linked to the gene set
under investigation is based on Fisher’s exact test. Further,
the gene sets were investigated by the Gene Set Enrichment
Analysis (GSEA; http://software.broadinstitute.org/
gsea/msigdb) which associates gene sets with pheno-
types using a predefined collection of data sets (4725
gene sets in the collection) [19].
BAM files generated from the exome sequencing were
used as the input for the derivation of genomic profiles
for analyses of CNAs using BioDiscovery software, NEXUS
8.0 (BioDiscovery, USA). Sixteen BAM files from adjacent
normal liver samples were used to create a study reference
according to the software instructions. BAM files from pri-
mary tumours and metastases were subsequently analysed
by standard recommendations of the manufacturer. The
quality of sequenced data from five patients were suboptimal
for CNA analysis, thus these patients were excluded from
further CNA analyses. Raw CNAs as numerical (involving
the whole chromosome) and segmental (involving part of
the chromosome in size at least of one chromosomal band)
were manually assessed. Local alterations in individual
genes, selected due to a conventionally accepted relevance
for CRC, were also analysed [20].
Validation by gene panel
Tissue from primary tumours were used for validation
of selected hotspot mutations identified by WES using the
AmpliSeq Colon Lung Cancer Panel version 2 (Thermo
Fisher Scientific, USA) comprising hotspot regions of 22
onco- and tumour suppressor genes. Eighteen primary
samples were included for validation analysis.
DNA was extracted from a 5 μm thick section of
formalin-fixed paraffin-embedded tumour sample using
QIAamp DNA Mini Kit (Qiagen) according to manufac-
turs instructions and quantified with a Qubit Photometer.
Ten ng of DNA was used for library preparation using the
Ion AmpliSeq Library Kit 2.0 and the AmpliSeq Colon
Lung Cancer Panel version 2 (Life Technologies). Sequen-
cing libraries were quantified by the Ion Library TaqMan ™
Quantification Kit and manually loaded on Ion 314 or 316
sequencing chips and sequenced > 500× in coverage by the
Ion Torrent Personal Genome Machine (Thermo Fisher
Scientific). Data analysis was carried out using the Torrent
Suite browser version 4.4 (Thermo Fisher Scientific) and
variants manually inspected in Integrative Genomics
Viewer (Broad Institute, USA).
Statistical analysis
All statistical analyses were performed using SPSS software
version 19 (IBM, USA). The correlation between the num-
ber of mutations and the location of the primary tumour,
between the number of mutations and neoadjuvant treat-
ment or not, and between percentages of shared mutations
and the localization of the primary tumour was analysed
by the Mann-Whitney U-test. The Kruskal-Wallis test was
used to determine whether the distribution of shared
mutations depended on the sequential order of resections.
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A generalized linear model was constructed to examine
whether the sequential order of the two resections,
chemotherapy (if given between the two operations), and
the localization of the primary tumour influenced the
number of private mutations. Tests with a p-value less
than 0.05 were considered statistically significant.
Results
Patient characteristics
Sixty-four consecutive patients were included in the
study. Samples from all three sites were successfully ob-
tained from 36 patients (Fig. 1). The remaining patients
were excluded due to cancellation of planned surgery,
acute surgery or the resected primary tumour was too
small to allow for tissue collection for the study. Eight
samples were excluded after the histological evaluation,
and an additional seven samples failed the quality con-
trols after sequencing. Thus, 21 patients remained,
resulting in a total of 63 samples. Three patients had
additional metachronous metastases (removed at a sub-
sequent liver resection) available for analysis (Fig. 1).
The characteristics of the 21 patients are listed in
Table 1. All tumours were microsatellite stable, i.e. had
normal expression of the four mismatch repair (MMR)
proteins MLH1, MSH2, MSH6 and PMS2. Immunohis-
tochemistry examination of these four proteins is stand-
ard procedure for all resected CRC patients in Denmark.
Classification of mutations in primary tumours and
metastases
An average of 180,285 gene variants was identified per
sample by the initial workflow. Filtering decreased the
number of variants to a mean of 470 per sample eligible
for manual visual identification, resulting in an average
of 73 (41–142) mutations per patient including shared
and private mutations from both sites. A mean of 92%
(72–100%) of variants designated as shared were identified
in the filtering process in both primary tumour and me-
tastasis, the remaining 8% were identified at the manual
visual control of the paired sites.
Transitions (TI; T↔C; G↔A) were identified in 62.0%
and transversions (TV; T↔A; G↔C; A↔C; T↔G) in
31.2%, giving a TI/TV ratio of 2.0 (range 1.0–3.8). There
was no difference in the TI/TV ratios between primary
tumours and metastases (p = 0.8).
In total, 1674 variants/mutations located in 1435 differ-
ent genes were identified in the 21 paired tumour samples,
with APC (76%), TP53 (57%) and KRAS (52%) being
the genes with the highest mutation rates. The most
frequently mutated genes in our cohort are presented
in Fig. 2. The average coverage reported by the CLC
workflow per sample had a mean of 47.2 in primary
tumours and 43.8 in metastases. There was no difference
in the coverage of the primary tumours and their paired
metastases (p = 0.25). The gene variants identified had an
average sequence coverage of 77.3.
The identified gene variants were subsequently assigned
a status of either shared mutation (S) (common between
the primary tumour and metastases), private to the
primary tumour (PP) or private to the metastases (PM).
Interestingly, mutations with a different status (i.e. shared
vs. private) had similar SIFT classification patterns (Fig. 3),
with nearly the same frequency of activating (S 2.2%, PM
1.0%, PP 1.5%) and damaging mutations (S 36.6%, PM
36.6%, PP 33.5%). Searching for known driver genes a total
of 117 called variants were identified in a driver gene,
ranging from 3 to 11 among the patients (median 5).
15.4% of these variants in driver genes were private.
Fig. 1 CONSORT flow diagram of patients reviewed for inclusion in the study
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Genes with a private mutation in the metastasis were
submitted to IPA. These genes were found to be involved
in processes such as cell movement, cell-to-cell signalling
and interaction, cell death and survival, and cell morph-
ology (IPA; p < 0.05). Assuming that mutations may have
an effect on the expression of the mutated gene, GSEA
analysis was undertaken and disclosed that private
mutations in metastases resembled signatures found in
a subset of patients with nasopharyngeal carcinoma
(GSEA; ODD_NASOPHARYNGEAL_CARCINOMA_UP;
FDR q-value 8.33E-5).
Specificity of private mutations
Shared mutations were dominant with a median of 78%
ranging from 50 to 96%. About one tenth of all mutations
identified were private in the primary tumour (12%) as
well as in the metastases (12%). Hence, some mutations
from the primary tumour were not identified in the
metastases or had evolved in the primary tumour after
metastatic spread and some evolved in the metastases.
The relatively high proportion of shared mutations indi-
cates that the primary profile is largely maintained during
disease progression. The occurrence of shared versus
private mutations is summarised in Fig. 4.
Concordance between mutations in the primary tumour
and the synchronous liver metastasis was seen in APC,
KRAS, NRAS,TP53 and BRAF genes (100%), while discord-
ance among those with a mutation was seen in, amongst
others, PIK3CA (50%), AHNAK2 (20%), SMAD4 (17%),
BCLAF1 (50%), and ARHGAP32 (100%).
In total, 196 private mutations were identified in
the liver metastases and 194 private mutations were
found in the primary tumours of the 21 patients
(Additional file 1: Table S1). All 390 private mutations
were unique, i.e. none were seen as private in two or
more patients. However, 74 of the private mutations
were also seen in other mutations as shared. Figure 5
shows the functions of these genes distributed into
six categories: DNA or RNA binding, cell cycle and
apoptosis, metabolism, signalling, extracellular matrix
or cytoskeleton and unknown, with 25% categorized
as important for signalling and 20% involved in DNA
or RNA binding.
Interestingly, one patient had two primary T3 tumours
located in the ascending colon with only 3 cm in between.
The tumours harboured 45 and 64 mutations, respectively.
None of the mutations found in the primary tumours were
shared, reflecting different origins of these lesions. Of note,
two different activating KRAS mutations (KRAS c.38G >A,
KRAS c.436G >A) were identified in these tumours. The
examined liver metastasis in this patient had 79% shared
mutations with the primary tumour harbouring the KRAS
c.38G >A mutation, while no mutations were shared with
the other primary tumour.
With the reservation of possible normal tissue con-
tamination influencing the frequencies, a median of two
mutations per primary tumour/metastases pair proved
to have an increase of more than 30 in allel frequency.
Noteworthy, TP53 mutations (c.944C > T; c.794 T > C;
c.817C >T in three patients (36%→ 78%; 11→ 47%; 41→
73%), a SMAD4 (c.1067C >T) in one patient (24%→ 73%)
and an AKT (c.49G > A) mutation in one patient
(37%→ 84%). A total of 35 of 36 mutations identified
by WES was validated by the hot spot panel i.e. only
one mutation (KRAS, c.38G > A) was not identified by
the hot spot panel.
Table 1 Patient characteristics
Characteristics n = 21
Age Median 68 (38–84)
Gender
Male 12 (57%)
Female 9 (43%)
Primary tumour location
Right 9 (43%)
Left 12 (57%)
Resection
Concurrent 5 (24%)
Subsequent – liver first 5 (24%)
Subsequent – primary first 11 (52%)
Time between resections Median 36 days
Treatment
Chemonaïve 11 (52%)
Both tumours 7 (33%)
Only metastasis 2 (10%)
Only primary 1 (5%)
Neoadjuvant treatment
CAPOX 2 (10%)
CAPOX + bevacizumab 2 (10%)
FOLFIRI + cetuximab 1 (5%)
FOLFOX + cetuximab 2 (10%)
Between resections
CAPOX 2 (10%)
FOLFOX 1 (5%)
Number metastases Median 2 (1–5)
Microsatellite stability 21 (100%)
Tumour stage
Stage IV 21 (100%)
Tumour differentiation
Low 2 (10%)
High 19 (90%)
CAPOX denotes capecitabine and oxaliplatin, FOLFIRI signifies 5-fluorouracil
and irinotecan; and FOLFOX indicates 5-fluorouracil and oxaliplatin
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Metachronous liver metastasis
Three patients operated for a subsequent relapse had an
additional, metachronous liver metastasis sequenced,
patients #5, 6 and 22 as corresponding to patient ID in
Figs. 2 and 4. The distributions of mutations in the pri-
mary tumour and in the syn- and metachronous liver
metastases, respectively, are shown in Fig. 6. The speci-
men from the primary tumour of patient #22 had a
high degree of normal tissue and was therefore omitted,
leaving only the synchronous and metachronous liver
metastases for comparison. Among all mutations iden-
tified in #5 and #6, 48 and 46% was seen as shared
between all three sites, respectively, and 23% (#5) and
32% (#6) of identified variants proved to be private in
the metachronous metastases. As for the two primary
tumours, 13% (#5) and 15% (#6) of all variants identified
in the patient were private mutations, i.e. mutations that
may have evolved after the metastatic spread or been lost
Fig. 2 The genes in which mutations were most highly represented are illustrated. Blue-filled box denotes mutation shared between the primary
tumour and the metastasis, light green-filled box signifies mutation private to the primary tumour and dark green-filled box indicates mutation
private to the metastasis. Shared mutation refers to the exact same mutation and not just a mutation located in the same gene
Fig. 3 The characterization of mutations according to the SIFT classification divided into private mutations to the primary tumour (PP), private
mutations to the metastases (PM) and shared mutations (S). A nearly identical distribution of activating and damaging mutations relative to the
private and shared mutations was revealed
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during the process of dissemination. Private mutations in
the three metachronous metastases were, amongst others,
SORBS1, AR, CNTN1, TIMP3, PLK1, SIRT7, DNAH5 and
BRCA2.
Comparison of mutational burden according to primary
tumour location
Right- and left-sided bowel tumours are evolutionarily
different, deriving from mid- and hindgut, respectively.
This may explain the different mutation patterns and
biological behaviour comparing right- with left-sided
bowel cancers [21, 22]. Therefore, the numbers of
mutations per patient (S + PP + PM) in left- versus
right-sided primary tumours were compared. The number
of mutations (i.e the mutational burden) was significantly
higher in the right-sided tumours (median of 102 vs. 66, p
= 0.004; Fig. 7). Comparing only mutations present in the
primary tumour (S + PP) of left- versus right-sided, a sig-
nificant difference was still present (p = 0.021). Moreover,
patients with right-sided tumours had significantly fewer
shared mutations (75% vs. 82%, p = 0.023; Fig. 7).
Mutational profile and chemotherapy
The number of mutations was not related to whether
the patient had received neoadjuvant treatment or was
chemonaïve (p = 0.4). Similarly, chemotherapy between
the first and second resection had no impact on the per-
centages of shared mutations (p = 1.0), neither did the
sequential order of resection history: liver before bowel or
vice versa (p = 0.3). No confounding was observed from
‘chemotherapy between bowel and liver surgery’ or ‘sequen-
tial order of operations’ (generalized linear model). How-
ever, this outcome of our analyses must be interpreted
cautiously since the study was not powered to answer this
question. Few patients received chemotherapy between
their resections and number of cycles varied from patient
to patient. The time spans between resection of the
synchronous and the metachronous liver metastasis
were 14, 18 and 3 months, respectively. At this point, 15,
8 and 1 cycle (s) of chemotherapy had been administered.
Copy number aberrations
We further used the sequence data to derive CNA profiles.
Adjacent normal liver tissue samples were used as a ref-
erence. Numerical aberrations occurred to a higher ex-
tent in chromosomes 7, 8, 13, 18 and 20, and segmental
Fig. 4 Histogram showing the mutational number according to each patient divided into shared and private mutations. Blue represents shared
mutations, light green signifies mutations private to the primary tumour and dark green indicates mutations private to the metastases
Fig. 5 Functional categories of the genes private to the metastasis
and categorized according to SIFT as damaging or activating. In
total, 76 genes were included. The GO annotations in the Ingenuity
software were used for functional assessment. The genes were
grouped according to the functional categories: DNA/RNA binding,
cell cycle – apoptosis, metabolism, signalling, ECM – cytoskeleton,
and unknown
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aberrations were more common in chromosomes 1, 5, 8
and 18 (Additional file 2: Table S2). Allelic frequencies for
primary tumour and metastases are summarized in Fig. 8a.
Comparing numerical and segmental aberrations in the
primary tumour versus metastasis, every pair differed in at
least one of these raw chromosomal aberrations (Fig. 8b).
Interestingly, there was a trend that metastases expressing
a high number of novel numerical aberrations had fewer
segmental aberrations. Conversely metastases with many
novel segmental aberrations had fewer numerical aberra-
tions (Fig. 8b).
Local CNAs of individual genes, selected because of their
relevance in CRC, showed almost no differences between
the primary tumour and metastasis (Additional file 3:
Table S3). This is in agreement with our observations
at the mutational level, where driver events remained
unaltered during tumour progression. SMAD2, SMAD4,
TP53 and AURKA were affected by CNAs in a high
proportion of the patients, i.e. in 11, 11, 8 and 6 out of
16 patients, respectively.
Damaging private mutations (according to the SIFT
classification) identified in the metastases were investigated
Fig. 6 Mutations located in the primary tumour, synchronous liver metastasis and metachronous liver metastasis. Patient(#) 5 and 6 had all three
sites successful sequenced and analysed, #22 had a primary tumour with insufficient residual tumour content and therefore not analysed. The bar
of each site (primary tumour, synchronous metastasis, relapse) are coloured according to the identified variants being shared with another site
or private
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to determine whether CNAs accompanied the mutation.
Twelve of the mutated genes showed CNAs, nine with a
loss of heterogeneity (Additional file 4: Table S4).
Discussion
Several studies of various cancer types have suggested
that the mutation status of the primary tumour has limita-
tions as an indicator for the selection of treatment of the
metastatic disease. Studies of breast cancer [23, 24] and
central nervous system tumours [25] have provided
evidence supporting the view that primary lesions and
metastases are individual genomic entities; however,
with regard to CRC, solid evidence still remains to be
presented. The present study compared the genomic
profiles of paired primary tumours and synchronous
liver metastases from CRC patients and found from 50
to 96% concordance between the primary tumour and
the metastasis in the investigated patients, i.e. these
data are not in support of the view of genomic entities.
The prevailing mutations were APC, KRAS and TP53,
which is in accordance with data reported by The Cancer
Genome Atlas Network [26]. In addition, a total of 1435
different genes were found to be mutated, illustrating the
complexity and therefore the importance of defining
specific profiles if clinically applicable conclusions are to
be possible. Furthermore, only a few mutations were simi-
lar among the 21 investigated patients, indicating that a
large group of patients has to be examined to determine
whether a correlation between a new specific mutations
and a specific treatment do exist. The example of the
patient with two closely located primary right-sided
tumours having completely different genomic profiles
emphasises the importance of mutational analysis of all
primary tumours of a patient and of the metastasis if it
is relevant for the treatment strategy.
The present results add to the body of evidence that
microsatellite stable CRC has an average mutation rate
of 60 [27]. The functional impact of mutations was
further examined using in silico modelling by applying
the SIFT classification. According to SIFT, 38.2% of the
mutations were found to be either damaging or activating.
Although in general in silico analysis has a relatively low
specificity and high sensitivity making direct interpretation
difficult in a clinical context, we found SIFT to be support-
ive for comparisons of the composition of gene variants.
Our analyses revealed similar distributions of activating,
damaging and tolerated mutations within the group of
private mutations compared to the group of shared muta-
tions, suggesting a lack of selectivity in the occurrence of
private mutations. Most of the identified variants are prob-
ably passenger mutations, fewer expected to be in driver
genes. The number of known cancer driver genes is still
limited but growing with increasing knowledge about
the function of cancer specific genes. The majority of
the observed mutation variants in the cancer driver
genes in our set of genes were present in both primary
Fig. 7 Left panel: Box plot illustrating the number of mutations according to the location of the primary tumour. A significantly higher number of
mutations (mutational burden) was observed in patients with a right-sided tumour (p = 0.004). Right panel: Box plot illustrating the percentage of
shared mutations according to the location of the primary tumour. A significantly higher degree of shared variants was seen in patients with a
left-sided tumour (p = 0.023)
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tumour and metastasis. It has previously been implied
that at least three rate-limiting mutations are required
to develop late-stage CRC [28]. Based on the observations
that polyps with mutations in the KRAS gene do not
develop to cancer and that hyperplastic polyps do not
carry a mutation in the APC gene, it seems reasonable to
speculate that the first rate-limiting step in the develop-
ment of CRC are mutations in the APC pathway [29]. This
theory is supported by the fact that small adenomas,
advanced adenomas and carcinomas have almost the same
frequency of mutations in the APC gene [30], and may
explain why we saw all mutations in the APC gene as
shared. Studies comparing the primary tumour with
metastases are few in number and have mostly been
performed on a panel of selected genes, with a high
degree of concordance being reported [9, 31–33]. It appears
that investigations focusing on a few genes result in a high
concordance but expanding the panel of genes to include
less common ones leads to a higher degree of discordance.
We found a concordance of 50 to 96% of the mutational
profile of the primary tumour compared to synchronous
liver metastases. The number of private mutations may
reflect events during the time from metastatic seeding to
settling and metastatic growth in the liver. If the metastatic
spread occurs early in the tumour development, a
higher degree of diversity would be expected. Further, it
is acknowledged that primary tumours can be very
heterogeneous. This can be explained by the branched
evolution, where subclones grow side-by-side progressing
simultaneously and new subclones appear as new muta-
tions develop. The number of different mutations between
two cell samples is supposed to reflect the number of
generations passed from the origin in a common mother
cell. Several studies have shown a high degree of heterogen-
eity in primary tumours, not present to the same degree in
metastases [34]. Sampling from another clone in the pri-
mary than the one which gave rise to the liver metastasis
may lead to more private mutations in both. A study
including several tumour types investigated tumour
phylogenetic, and found a paraphyletic growth pattern
in metastases indicating that there is no linear-specific
event required to propagate metastasizing. This is in
line with our finding of high inter-patient diversity, and
of early driver genes seen in several patients. Zhao et al.
further described drivers as KRAS and TP53 as early,
PIK3CA and KMT2D midway events, and ALK and
KMT2C to be late driver events [35].
The level of sequencing depth is important for the
identified frequency of private mutations. It cannot be
excluded that a few private mutations might not be private
if the sequencing depths had been even higher; however,
as private mutations were manually identified by the visual
inspection of mapped genes we believe that it can only
be very few. Furthermore, the average sequencing depth
was not different between the primary tumour and the
metastases.
High concordance was seen in the hot spot panel
validating shared as well as some private mutations. A
Fig. 8 a) Frequency plot of copy number aberrations in primary tumour (upper plot) and synchronous liver metastases (lower plot). Red indicates
deletions and blue indicates copy number gains. b) Histogram illustrating of copy number aberrations – numerical as well as segmental - in 16
pairs of primary tumour and synchronous liver metastasis. Patients on the x-axis are numbered as in Figs. 3 and 5
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single KRAS mutation was not confirmed in the validation
analysis, most likely due to heterogeneity in the primary
tumour.
An NRAS mutation was found in one and KRAS muta-
tions were found in 11 of 21 patients in this series and all
were common. This is in accordance with previous findings
[8–10] and supports the general praxis of analysing the
RAS status in whatever tissue is available, primary tumour
or metastasis. In general, studies on predictive factors relate
likelihood of response to biomarker status of the primary
tumour [36, 37]. This practice, however, may miss possible
correlations due to a mutational status based on the
primary tumour rather than the metastases. We found
from 4 to 50% private mutations, meaning that if these
patients were included in a biomarker study there
would be a substantial risk of relating outcome to gene
mutations being private to one site. Most of the identified
variants are though assumed to be passenger mutations.
Among identified variants in driver genes only few were
private. As an example, the gene PIK3CA showed a muta-
tion in the primary tumour but not in the metastases. A
mutation in this gene may have an impact on the sensitivity
to PI3K/AKT/mTOR inhibitors [38, 39]. With the exception
of mutations in the APC and KRAS genes, it is not possible
to point out genes which rarely occur as private mutations.
In this study, we found the well-known driver genes
MAPK1, PIK3CA and SMAD4 to be private to either
the primary tumour or the metastasis. Even though a
mutation is present in a driver gene and might have an
important role in the tumourigenesis it will not necessarily
be a potential biomarker. In our current clinic setting only
the KRAS, NRAS and BRAF status have importance for
the treatment strategy but hopefully more will be identi-
fied. In general, predictive genetic biomarkers should be
tested on tissue from the metastases that are the target for
treatment.
A few of the found private mutations were categorised
as activating and so these changes will most likely elicit
a change in the cell. Mutations categorised as damaging
are more questionable regarding whether they actually
have an influence on the tumour. Since it is not possible
to directly extrapolate the frequency of a found mutation
in the whole-exome sequencing data, one can only guess
whether the mutation is present on one or two alleles
and in all the samples. Our analysis was therefore
extended to include a copy number variant analysis to
determine whether some of the private mutations in the
metastases were coupled with copy number aberrations.
Twelve of the identified private mutations in the metasta-
ses were shown to have a copy number aberration at their
location as well, thus increasing the likelihood that the
functions of the genes are affected. In this study, copy
number changes were most prominent in chromosomes
1, 5, 7, 8, 13, 18 and 20, which is similar to the findings of
other studies [40, 41]. Particular aberrations in chromo-
somes 8 and 20 have been reported to be correlated to
tumour progression.
Right- and left-sided bowel tumours derive embryo-
logically from the mid- and hindgut, respectively [42].
We found a higher number of mutations in right-sided
tumours compared to left-sided ones. The difference
could not be related to mismatch repair insufficiency
since all tumours in this study were microsatellite stable.
Furthermore, we found a lower degree of concordance
between the primary tumour and liver metastases in
patients with right-sided tumours. This is most likely a
basic biological characteristic rather than a diagnostic-delay
characteristic for right-sided cancers where the tumour
tends to lead to symptoms considerably later than left-sided
tumours [43].
Conclusion
In this study of CRC considerable concordance was seen
between mutations in the primary tumour and synchron-
ous liver metastases, although both harbour many private
mutations. Larger, prospective investigations are needed
to clarify the therapeutic and prognostic implications of
private mutations. Regarding K- and NRAS status, con-
cordance is normal, supporting the current praxis to use
whatever tissue is available. The mutational profiles of
primary tumours may prove insufficient in a future where
novel drugs might target mutations which frequently
occur privately. However, our data do not point out gene
mutations that are rarely found to be common.
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